Making treatment decisions in hemophilia based on available safety data.

Makris, Mike;Hermans, Cédric
(2021) Journal of thrombosis and haemostasis : JTH — Vol. 19, n° 4, p. 1138-1139 (2021)

Files

2021_Makris_J_Thromb_Haemost.pdf
  • Open Access
  • Adobe PDF
  • 265.62 KB
Download

Details

Authors
Abstract
The availability of emicizumab (Hemlibra) for the treatment of hemophilia A has been the most disruptive therapy to treat the condition since factor VIII (FVIII) concentrate was introduced. While for patients with antibodies to FVIII (inhibitors) this treatment has been life changing in dramatically reducing the annual bleed rate, for non-inhibitor patients on good FVIII prophylaxis the benefits are less clear. For non-inhibitor patients the benefit of emicizumab is largely that of convenience because it can be given subcutaneously every 1, 2, or 4 weeks rather than intravenously two to three times weekly. [...]
Affiliations

Citations

  • APA
  • Chicago
  • FWB

Makris, M., & Hermans, C. (2021). Making treatment decisions in hemophilia based on available safety data. Journal of thrombosis and haemostasis : JTH, 19(4), 1138-1139. https://doi.org/10.1111/jth.15255 (Original work published 2021)